Eric I Richman's Net Worth
$10.6 Million
Who is Eric I Richman?
Eric I Richman has an estimated net worth of $10.6 Million. This is based on reported shares across multiple companies, which include Lev Pharmaceuticals Inc, PHARMATHENE, INC, ADMA BIOLOGICS, INC., NeuBase Therapeutics, Inc., and Gain Therapeutics, Inc..
SEC CIK
Eric I Richman's CIK is 0001313876
Past Insider Trading and Trends
2016 was Eric I Richman's most active year for acquiring shares with 17 total transactions. Eric I Richman's most active month to acquire stocks was the month of October. 2016 was Eric I Richman's most active year for disposing of shares, totalling 21 transactions. Eric I Richman's most active month to dispose stocks was the month of March. 2016 saw Eric I Richman paying a total of $1,695,788.54 for 1,091,354 shares, this is the most they've acquired in one year. In 2016 Eric I Richman cashed out on 1,403,475 shares for a total of $750,466.20, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Lev Pharmaceuticals Inc No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 29 - Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
PHARMATHENE, INC (ALT) Snapshot price: $10.51
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +116.75% | 483.73K |
$1.85 | $895,213.18 | 898.05K |
Nov 22
| |||
Form 4
| +134.32% | 237.5K |
$1.45 | $343,625.00 | 414.32K |
Sep 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 1
| |||
Form 4
|
—
|
0
|
$1.70 | -$332,338.36 | 176.82K |
Scheduled
|
Apr 13
| ||
Form 4
|
—
|
0
|
$1.98 | -$5,177.48 | 176.82K |
Scheduled
|
Apr 7 - Apr 8
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 12
| |||
Form 4
| -11.29% | -22.50K |
—
|
—
| 176.82K |
Mar 7
| |||
Form 4
| +60.33% | 75K |
—
|
—
| 199.32K |
Dec 7
| |||
Form 4
|
∞
| 10K |
$1.50 | $15,024.75 | 10K |
Nov 10
| |||
Form 4
| +25.17% | 25K |
—
|
—
| 124.32K |
Sep 30
| |||
Form 4
| -9.56% | -10.50K |
$3.40 | -$35,700.00 | 99.32K |
Mar 23
| |||
Form 4
| -2.71% | -3.06K |
$3.42 | -$10,454.94 | 109.82K |
Jan 21
| |||
Form 4
| +44.94% | 35K |
—
|
—
| 112.88K |
Dec 23
| |||
Form 4
| +10.35% | 7.31K |
$2.54 | $18,569.66 | 77.88K |
Nov 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 20
| |||
Form 4
| +16.51% | 10K |
$1.58 | $15,767.00 | 70.57K |
Jun 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 28
| |||
Form 4
| +101.91% | 30.57K |
—
|
—
| 60.57K |
Jan 21
| |||
Form 4
|
∞
| 30K |
—
|
—
| 30K |
Oct 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ADMA BIOLOGICS, INC. (ADMA) Snapshot price: $5.29
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +20.53% | 7.5K |
—
|
—
| 44.03K |
Feb 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 22
| |||
Form 4
| +16.71% | 5.23K |
$4.78 | $24,999.40 | 36.53K |
Jun 8
| |||
Form 4
| +396.83% | 25K |
$2.15 | $53,750.00 | 31.3K |
Nov 9
| |||
Form 4
| +80.00% | 2.8K |
$2.68 | $7,504.00 | 6.3K |
Jul 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 28
| |||
Form 4
|
∞
| 3.5K |
$7.88 | $27,570.00 | 3.5K |
Mar 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Apr 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
NeuBase Therapeutics, Inc. (NBSE) Snapshot price: $0.69
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 9
| |||
Form 4
| +9.44% | 3.88K |
$1.64 | $6,352.40 | 44.96K |
Mar 1 - Mar 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 19
| |||
Form 4
| +13.86% | 5K |
$5.00 | $25,000.00 | 41.08K |
Apr 26
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 9
| |||
Form 4
| +20.44% | 10.83K |
$6.00 | $64,998.00 | 63.83K |
Apr 30
| |||
Form 4
|
∞
| 25.25K |
—
|
—
| 25.25K |
Jul 12
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Gain Therapeutics, Inc. (GANX) Snapshot price: $4.64
CHIEF EXECUTIVE OFFICER
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +25.21% | 54.9K |
—
|
—
| 272.63K |
Sep 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 20
| |||
Form 4
| +1.15% | 2.48K |
$2.58 | $6,403.56 | 217.73K |
May 25
| |||
Form 4
| +6.56% | 13.26K |
$2.79 | $37,034.48 | 215.25K |
May 19 - May 20
| |||
Form 4/A
| +2.32% | 4.92K |
$7.87 | $38,716.45 | 216.82K |
Aug 16
| |||
Form 3/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +2.32% | 4.92K |
$7.87 | $38,716.45 | 216.82K |
Aug 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||